Literature DB >> 11074891

Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection?

K S Jeng1, I S Sheen, B F Chen, J Y Wu.   

Abstract

HYPOTHESIS: Mutant p53 gene has lost its tumor suppression function and is considered to be a very important step in hepatocellular carcinoma development. We propose that the mutant p53 gene plays a role in its invasiveness and prognosis after resection.
DESIGN: A case-controlled study.
SETTING: A referral center. PATIENTS: Seventy-nine consecutive patients who underwent surgical resection for hepatocellular carcinoma entered this study. INTERVENTION: Tissue sections of resected hepatocellular carcinoma (deparaffinized and rehydrated from formalin-fixed and paraffin-embedded sections) were incubated with antihuman p53 monoclonal antibody and immunostained. The p53 result was scored without prior knowledge of the patients' status. A 10% immunopositivity was regarded as the threshold value. MAIN OUTCOME MEASURE: The immunopositive rate of p53 was 69.6% (55 of 79 patients). The clinical variables (age, sex, associated liver cirrhosis, hepatitis B virus infection, hepatitis C virus infection, serum alpha-fetoprotein, and Child-Pugh class); the histological variables (size, capsule, vascular permeation; grade of differentiation, and multinodularity); and postoperative course (recurrence, tumor-free interval, death, and survival period) were correlated with p53 immunopositivity.
RESULTS: From univariate analysis, more patients with p53 positivity were male (92.7 vs 0%) (P<.001); had vascular permeation (80% vs 50%) (P =.007) (odds ratio [OR], 4.0); no complete capsule (83.6% vs 62.5%) (P =.04) (OR, 3.1); and daughter nodules (90.9% vs 70.8%) (P =.04) (OR, 4.1) than patients with negative p53 staining. From multivariate analysis, only sex and vascular permeation remained significant (P =.001 and P =.008, respectively). Although more patients with p53 positivity had tumor recurrence (78% vs 50%) (P =.01) and death (64% vs 33%) (P =. 01), the Cox proportional hazards model showed that p53 overexpression had only weak correlations with tumor-free interval and survival time (P =.09 and P =.08, respectively).
CONCLUSIONS: Our results show that the biological behavior of the mutant p53 gene is strongly related to the invasiveness of hepatocellular carcinoma and may also influence the postoperative course. We suggest that the immunopositivity of the mutant p53 gene has a predictive role in the prognosis of patients with resected hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2000        PMID: 11074891     DOI: 10.1001/archsurg.135.11.1329

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  20 in total

1.  Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization.

Authors:  Yong-Song Guan; Yuan Liu; Long Sun; Xiao Li; Qing He
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

2.  Molecular genetics of hepatocellular neoplasia.

Authors:  Shilpa Jain; Shashideep Singhal; Peng Lee; Ruliang Xu
Journal:  Am J Transl Res       Date:  2010-01-23       Impact factor: 4.060

3.  Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

Authors:  Rong-Ping Guo; Chong Zhong; Ming Shi; Chang-Qing Zhang; Wei Wei; Ya-Qi Zhang; Jin-Qing Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-09       Impact factor: 4.553

4.  Do the expressions of gap junction gene connexin messenger RNA in noncancerous liver remnants of patients with hepatocellular carcinoma correlate with postoperative recurrences?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Shou-Chuan Shih; Chin-Roa Kao; Po-Chuan Wang; Chih-Zen Chen; Wen-Hsing Chang; Horng-Yuan Wang; Li-Rung Shyung
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

5.  Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma.

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Shou-Chuan Shih; Chih-Roa Kao; Wen-Hsing Chang; Horng-Yuan Wang; Po-Chuan Wang; Tsang-En Wang; Li-Rung Shyung; Chih-Zen Chen
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

6.  Are gap junction gene connexins 26, 32 and 43 of prognostic values in hepatocellular carcinoma? A prospective study.

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Po-Chuan Wang; Shou-Chuan Shih; Wen-Hsing Chang; Horng-Yuan Wang; Chung-Chu Chen; Li-Rung Shyung
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

Review 7.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

8.  Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.

Authors:  George G Chen; Juanita L Merchant; Paul B S Lai; Rocky L K Ho; Xu Hu; Morihiro Okada; Sheng F Huang; Albert K K Chui; David J Law; Yong G Li; Wan Y Lau; Arthur K C Li
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

9.  Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study.

Authors:  Kuo-Shyang Jeng; I-Shyan Sheen; Yi-Ching Wang; Shu-Ling Gu; Chien-Ming Chu; Shou-Chuan Shih; Po-Chuan Wang; Wen-Hsing Chang; Horng-Yuan Wang
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

10.  Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?

Authors:  Kuo-Shyang Jeng; I-Shyan Sheen; Yi-Ching Wang; Shu-Ling Gu; Chien-Ming Chu; Shou-Chuan Shih; Po-Chuan Wang; Wen-Hsing Chang; Horng-Yuan Wang
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.